The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching
Abstract Purpose Whether the addition of tislelizumab to gemcitabine and cisplatin (GC) chemotherapy increases the incidence of myelosuppression has not been well established. This study identified the risk factors for the development of myelosuppression in patients with urothelial carcinoma (UC) af...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6807 |
| _version_ | 1827395160418287616 |
|---|---|
| author | Zhimin Gao Nienie Qi Xu Qin Zhen Li Gang Li Zewei Wang Junqi Wang Rumin Wen Hailong Li |
| author_facet | Zhimin Gao Nienie Qi Xu Qin Zhen Li Gang Li Zewei Wang Junqi Wang Rumin Wen Hailong Li |
| author_sort | Zhimin Gao |
| collection | DOAJ |
| description | Abstract Purpose Whether the addition of tislelizumab to gemcitabine and cisplatin (GC) chemotherapy increases the incidence of myelosuppression has not been well established. This study identified the risk factors for the development of myelosuppression in patients with urothelial carcinoma (UC) after receiving GC chemotherapy with or without tislelizumab. Materials and Methods We enrolled 192 UC patients who received GC with or without tislelizumab at the Affiliated Hospital of Xuzhou Medical University between July 2014 and November 2022. Patient baseline characteristics were included in the statistical analyses after adjusting for previously reported risk factors affecting survival using propensity score matching (1:1). Binary logistic regression analysis was used to identify the risk factors associated with posttreatment myelosuppression. Results A total of 192 patients were enrolled, of whom 96 were treated with tislelizumab plus gemcitabine and cisplatin (T + GC) and 96 with GC alone. The incidence of leukopenia, anemia, and thrombocytopenia of any grade was 50.0%, 70.8%, and 42.7%, respectively, in the T + GC group and 41.7%, 72.9%, and 20.8%, respectively, in the GC group. In multivariate analysis, patients aged over 70 years (OR = 2.486, 95% CI: 1.067–5.792, p = 0.035) and those who received T + GC (OR = 3.119, 95% CI: 1.576–6.173, p = 0.001) were more likely to develop thrombocytopenia. Patients aged over 70 years (OR = 3.213, 95% CI: 1.254–8.237, p = 0.015) were more likely to develop anemia, and patients with renal insufficiency (OR = 2.105, 95% CI: 1.035–4.280, p = 0.040) were more likely to develop leukopenia. Eventually, 99 (51.6%) patients with UC successfully completed all the treatment cycles. Conclusions This study demonstrates that the addition of tislelizumab to GC chemotherapy led to a considerable increase in the occurrence of thrombocytopenia, whereas no significant changes were observed regarding anemia or leukopenia. It is crucial to fully inform patients at increased risk for myelosuppression of potential risks and closely monitor changes in their blood routines. |
| first_indexed | 2024-03-08T18:27:45Z |
| format | Article |
| id | doaj.art-7b6ed0e89f754625834f2e261056ba3b |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-08T18:27:45Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-7b6ed0e89f754625834f2e261056ba3b2023-12-30T08:53:26ZengWileyCancer Medicine2045-76342023-12-011224220712208010.1002/cam4.6807The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matchingZhimin Gao0Nienie Qi1Xu Qin2Zhen Li3Gang Li4Zewei Wang5Junqi Wang6Rumin Wen7Hailong Li8Department of Urology The Affiliated Hospital of Xuzhou Medical University Xuzhou ChinaDepartment of Urology The Affiliated Hospital of Xuzhou Medical University Xuzhou ChinaDepartment of Urology The Affiliated Hospital of Xuzhou Medical University Xuzhou ChinaDepartment of Urology The Affiliated Hospital of Xuzhou Medical University Xuzhou ChinaDepartment of Urology The Affiliated Hospital of Xuzhou Medical University Xuzhou ChinaDepartment of Urology The Affiliated Hospital of Xuzhou Medical University Xuzhou ChinaDepartment of Urology The Affiliated Hospital of Xuzhou Medical University Xuzhou ChinaDepartment of Urology The Affiliated Hospital of Xuzhou Medical University Xuzhou ChinaDepartment of Urology The Affiliated Hospital of Xuzhou Medical University Xuzhou ChinaAbstract Purpose Whether the addition of tislelizumab to gemcitabine and cisplatin (GC) chemotherapy increases the incidence of myelosuppression has not been well established. This study identified the risk factors for the development of myelosuppression in patients with urothelial carcinoma (UC) after receiving GC chemotherapy with or without tislelizumab. Materials and Methods We enrolled 192 UC patients who received GC with or without tislelizumab at the Affiliated Hospital of Xuzhou Medical University between July 2014 and November 2022. Patient baseline characteristics were included in the statistical analyses after adjusting for previously reported risk factors affecting survival using propensity score matching (1:1). Binary logistic regression analysis was used to identify the risk factors associated with posttreatment myelosuppression. Results A total of 192 patients were enrolled, of whom 96 were treated with tislelizumab plus gemcitabine and cisplatin (T + GC) and 96 with GC alone. The incidence of leukopenia, anemia, and thrombocytopenia of any grade was 50.0%, 70.8%, and 42.7%, respectively, in the T + GC group and 41.7%, 72.9%, and 20.8%, respectively, in the GC group. In multivariate analysis, patients aged over 70 years (OR = 2.486, 95% CI: 1.067–5.792, p = 0.035) and those who received T + GC (OR = 3.119, 95% CI: 1.576–6.173, p = 0.001) were more likely to develop thrombocytopenia. Patients aged over 70 years (OR = 3.213, 95% CI: 1.254–8.237, p = 0.015) were more likely to develop anemia, and patients with renal insufficiency (OR = 2.105, 95% CI: 1.035–4.280, p = 0.040) were more likely to develop leukopenia. Eventually, 99 (51.6%) patients with UC successfully completed all the treatment cycles. Conclusions This study demonstrates that the addition of tislelizumab to GC chemotherapy led to a considerable increase in the occurrence of thrombocytopenia, whereas no significant changes were observed regarding anemia or leukopenia. It is crucial to fully inform patients at increased risk for myelosuppression of potential risks and closely monitor changes in their blood routines.https://doi.org/10.1002/cam4.6807cisplatingemcitabinemyelosuppressionrisk factorstislelizumaburothelial carcinoma |
| spellingShingle | Zhimin Gao Nienie Qi Xu Qin Zhen Li Gang Li Zewei Wang Junqi Wang Rumin Wen Hailong Li The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching Cancer Medicine cisplatin gemcitabine myelosuppression risk factors tislelizumab urothelial carcinoma |
| title | The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching |
| title_full | The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching |
| title_fullStr | The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching |
| title_full_unstemmed | The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching |
| title_short | The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching |
| title_sort | addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma a single center study based on propensity score matching |
| topic | cisplatin gemcitabine myelosuppression risk factors tislelizumab urothelial carcinoma |
| url | https://doi.org/10.1002/cam4.6807 |
| work_keys_str_mv | AT zhimingao theadditionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT nienieqi theadditionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT xuqin theadditionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT zhenli theadditionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT gangli theadditionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT zeweiwang theadditionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT junqiwang theadditionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT ruminwen theadditionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT hailongli theadditionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT zhimingao additionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT nienieqi additionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT xuqin additionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT zhenli additionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT gangli additionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT zeweiwang additionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT junqiwang additionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT ruminwen additionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching AT hailongli additionoftislelizumabtogemcitabineandcisplatinchemotherapyincreasesthrombocytopeniainpatientswithurothelialcarcinomaasinglecenterstudybasedonpropensityscorematching |